泌尿器がん化学療法の進歩と問題点

電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

3,025 円(税込)

購入する

商品紹介

第１０回泌尿器がん化学療法研会では、アメリカから2名の特別講師を招き、パネル・ディスカッションの形式で開催、それを纏めたのが本書です。(序文より)

目次

  • 表紙
  • 序言
  • 目次
  • 特別講演
  • Recent Advances in Urologic Cancer Nasser Javadopour
  • I 腎細胞癌
  • 腎細胞癌治療についてのoverview
  • インターフェロン(INF)を主体とした療法
  • 腎細胞癌の化学療法
  • 腎癌に対するautologous LAK cellsによるadoptive immunotherapy
  • 腎癌のホルモン療法
  • 腎細胞癌に対するマイトマイシンCマイクロカプセル(MMC-mc)化学塞栓療法の手術補助効果
  • 腎細胞癌化学療法の問題点
  • 総合討論
  • II 膀胱癌
  • 膀胱癌bladder cancerの化学療法の進歩と問題点―膀胱癌治療のoverview―
  • 尿路移行上皮癌に対するTHPの効果
  • 膀胱癌の同調多剤併用化学療法(VPM-CisCF)
  • 浸潤性膀胱癌に対する集学的療法
  • 膀胱癌に対する集学的療法
  • 膀胱癌における補助療法としての阻血動注化学療法
  • 膀胱癌に対する膀胱全摘術後の補助化学療法
  • 膀胱癌化学療法の問題点
  • 総合討論
  • III 前立腺癌
  • 前立腺癌治療のoverview
  • 内分泌療法の限界と化学療法の適応について
  • 前立腺癌の化学療法
  • 前立腺癌に対する化学療法の効果
  • 前立腺癌に対する化学療法の効果
  • 化学療法剤の適応
  • 前立腺癌に対するUFTのphase II study
  • 総合討論
  • IV 睾丸腫瘍
  • 日本における睾丸腫瘍の特性と問題点
  • 睾丸腫瘍の化学療法―PVB療法を中心に―
  • 進行性睾丸腫瘍に対するVAB-6療法について
  • 化学療法を中心とした集学的治療の現況
  • 集学的治療の現況と問題点―放射線との併用―
  • 化学療法の副作用対策とその意義
  • 精巣腫瘍の診断, 治療における腫瘍マーカーの意義
  • 睾丸腫瘍の治療における問題点
  • 総合討論
  • 特別講演
  • Recent Advances Bladder Cancer Research
  • 奥付

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

特別講演

P.18 掲載の参考文献
1) Robson, C. J., Churchill, B. M., Anderson, W.:The results of radical nephrectomy for renal cell carcinoma. J. Urol., 101:297～301, 1969.
 
2) Bottiger, L. E.:Prognosis in renal carcinoma. Cancer, 28:780～787, 1970.
 
3) Skinner, D. G., Colvin, R. B., Vermillion, C. D., et al.:Diagnosis and management of renal cell carcinoma-a clinical pathological study of 309 cases. Cancer, 28:1165～1176, 1971.
 
4) Katz, S. A., Davis, J. E.:Renal adenocarcinoma-prognosis and treatment reflected by surviral. Urology., 10:10～11, 1977.
 
5) Waters, W. B., Richie, J. B.:Aggressive surgical approach to renal cell carcinoma:review of 130 cases. J. Urol., 122:306～309, 1979.
 
6) Boxer, R. J., Waisman, J., Lieber, M. M., et al.:Renal carcinoma-computer analysis of 96 patients treated by nephrectomy. J. Urol, 122:598～601, 1979.
 
7) McNichols, D. W., Segura, J. W., De Weerd, J. M.:Renal cell carcinoma:long-term survival and late recurrence. J. Urol., 126:17～23, 1981.
 
8) 阿曽佳郎, 田島 惇:腎癌の治療成績とそれを左右する因子-とくに尿路外症状との関連について-. 癌の臨床, 27:867～876, 1981.
 
9) 里見佳昭, 仙賀裕, 福田百邦, 他:腎癌患者の10年生存率及び10年以上生存例の検討. 日泌尿会誌, 75:118～125, 1984.
 
10) 増田富士男:腎細胞癌の治療成績を左右する因子-とくに宿主側, 腫瘍側の因子について-. 日泌尿会誌, 76:904～912, 1985.
 
11) 中西正一郎, 柏木 明, 斯波光生, 他:腎細胞癌の病理組織学的検討-核型による悪性度と予後について-. 日泌尿会誌, 75:1637～1345, 1984.
 
P.28 掲載の参考文献
1) 海老名卓郎, 斎藤元男:インターフェロンの抗腫瘍作用. 癌と化学療法 11:24-35, 1984.
 
2) Quesada J R, Swanson D A, Trindale A. et al. Renal cell carcinoma:Antitumor effects of luekocyte interferon. Cancer Res. 43:940-947, 1983.
 
3) DeKernion J B, Sarna G, Figlin R, et al:The treatment of renal cell carcinoma with human leukocyte alpha-interferon. J. Urol. 130:1063-1066, 1983.
PubMed
4) 小野佳成, 大島伸一, 藤田民夫・他:ヒトリンパ芽球インターフェロン(HLBI)の腎細胞癌への効果. 日癌治 18:962-968, 1983.
 
5) 増田富士男, 鈴木正泰, 池本庸・他:腎細胞癌に対するHuman Lymphoblastoid Interferon療法. 泌尿紀要 30:615-619, 1984.
 
6) 里見佳昭, 仙賀裕, 福田百邦・他:腎細胞癌の化学療法. 第4報インターフェロン療法. 日泌尿会誌 75:909-916, 1984.
 
7) Marumo K, Mukai M, Hayakawa M, et al:Humam lymphoblastoid interferon therapy for advanced renal cell cercinoma. Urol. 24:567-571, 1984.
 
8) Kirkwood J M, Harris J E, Vera R, et al:A randomized study of low and high doses of leukocyte alpha-interferon in metastatic renal cell carcinoma. The American Cancer Society Collaborative Trial. Cancer Res. 45:863-871, 1985.
 
9) 川村寿一, 山内民男, 橋村孝幸・他:腎細胞癌に対するα型インターフェロンの治療成績. 泌尿紀要 31:377-386, 1985.
 
10) 新島端夫:組換え型ヒト白血球インターフェロンA(γIFN-αA)の泌尿性器系悪性腫瘍に対する臨床効果の検討. 癌と化学療法 12:921-927, 1985.
 
11) 吉田修, 川村寿一, 岡部達士郎・他:腎癌の現況と問題点. 診断と治療 68:499-505, 1980.
 
12) 山内民男, 川村寿一, 吉田 修・他:腎癌に対するα型インターフェロンの抗腫瘍効果検討-病理剖検例を中心に. 泌尿紀要 31:1539-1552, 1985.
 
13) Figlin R A, deKernion J B, Maldazys J, et al:Treatment of renal cell carcinoma with alpha (human leukocyte) interferon and vinblastine in combination. A phase I-II trial. Cancer Treat. Rep. 69:263-267, 1985.
PubMed
P.47 掲載の参考文献
1) Grimm EA, Mazumber A, Zhang H Z, et al:The lymphokine activated killer cell phenomenon lysis of NK resistant fresh solid tumor cells by IL 2-activated autologous human peripheral blood lymphocytes. J. Exp. Med 155:1823, 1982.
 
2) Nakano E, Fujioka H, Sonoda T, et al:Autologous mixed lymphocyte tumor cell culture in patients with renal cell carcinoma. J. Urol. 131:223, 1984.
PubMed
3) Robson C J, Churchill B M and Anderson W.:The results of radical nephrectomy for renal cell carcinoma. J. Urol. 101:297, 1969.
PubMed
4) Skinner D G, Colvin R B, Vermillion C D, et al:Diagnosis and management of renal cell carcinoma. Aclinical and pathological study of 309 cases. Cancer, 28:1165, 1971.
 
5) Nakano E, Tada Y, Sonoda T, et al:Cytotoxic activity of peripheral blood lymphocytes grown with interleukin 2 against autologous cultured tumor cells in patients with renal cell carcinoma:preliminary report. J. Urol. 134:24, 1985.
PubMed
P.58 掲載の参考文献
1) Bloom HJG :Tumours of the kidney and ureter. (Edited by Sir Riches, E. ) p. 311, E & S Ltd., Edinburch and London, 1964.
 
2) Hrushesky WJ, and Murphy GP:Current status of the therapy of advanced renal carcinoma. J. Surg. Oncol. 9:277-288, 1977.
 
3) Matthews VS, Kirkman H, and Bacon RL:Kidney damage in golden hamster following chronic administration of diethylstilboesterol and sesami oil. Proc. Soc. Exp. Biol. 66:195-196, 1947.
 
4) 里見佳昭, 岡本重禮:腎癌のホルモン療法. 日泌尿会誌 63:939-950, 1972.
 
5) Satomi Y, Takai S, Kondo I, Fukushima S, and Furuhata A:Postoperative prophylactic use of progesterone in renal cell carcinoma. J. Urol. 128:919-922, 1982.
PubMed
6) Pizzocaro G, DiFronzo G, Piva L, Salvioni R, Cappelletti V, Giongo A, et al:Adjunctive medroxyprogesterone acetate to radical nephrectomy in category MO renal cell carcinoma. Preliminary report of a prospective randomized trial. Eur. Urol. 9:202-206, 1983.
 
P.69 掲載の参考文献
1) McDonald M W:Review Article;Current therapy for renal cell carcinoma. J. Urol. 127 211-217, 1982.
PubMed
2) 加藤哲郎:泌尿器科領域における動脈塞栓療法. 日本医事新報 2895:13-18, 1979.
 
3) Kato T, Nemoto R, Mori H, et al:Transcatheter arterial chemoemboization of renal cell carcinoma with microencapsulated mitomycin C. J. Urol. 125:19-25, 1981.
 
4) Kato T, Nemoto R, Mori H, et al:Arterial chemoembolization with microencapsulated anticancer drug;an approach to selective cancer chemotherapy with sustained effects. JAMA, 245:1123-1126, 1981.
PubMed
5) Kato T:Encapsulated drugs in targeted cancer therapy. In, Controlled Drug Delivery, S. E. Bruck (Ed. ), Vol. II, pp. 189-240, CRC Press, Boca Raton, 1983.
 
6) 阿部良悦, 加藤哲郎, 森 久, 他:腎癌に対するマイトマイシンCマイクロカプセル術前補助療法. 日癌治 20:535-541, 1985.
 
P.82 掲載の参考文献
1) Poster DS, et al:Current status of chemotherapy, hormonal therapy, and immunotherapy in the treatment of renal cell carcinoma. Am J CIin Oncol., 5:53, 1982.
 
2) Carter S K, Wasserman T H:The chemotherapy of urologic cancer. Cancer, 36:729, 1975.
PubMed
3) Gralla R J, Yagoda A:Phase II evaluation of chlorozotocin in patients with renal cell carcinoma. Cancer Treat Rep., 63 (6):1007, 1979.
PubMed
4) Talley R W:Chemotherapy in cancer of the kidney. Presented at the Urologic Cancer Meeting. Washington, D. C., 1972. (cited from 1)
 
5) Wajsman Z:High dose cyclophosphamide(CPM)in metastatic renal cell cancer. ASCO Abstr. C-413, 1980.
 
6) Rao M K, Soloway M S:Medroxyprogesterone in metastatic renal cell carcinoma. South Med J 73(2):274, 1980.
 
7) Lang E K, et al:Transcatheter embolization of renal cell carcinoma with radioactive infarct particles. Radiology 147:413, 1983.
PubMed
8) Swanson D A, et al:Angioinfarction plus nephrectomy for metastatic renal cell carcinoma;An update. J. Urol., 130:449, 1983.
PubMed
9) Kakizoe T, et al:Chemotherapy by bronchial arterial infusion for pulmonary metastases of renal cell carcinoma. J. Uro, 131:1053, 1984.
 
10) DeKernion J B:Treatment of advanced renal cell carcinoma--traditional methods and innovative approaches. J. Urol., 130:2, 1983.
PubMed
11) Hrushesky W J, Murphy G P:Current status of therapy of advanced renal carcinoma. J. Surg. Oncol., 9:277, 1977.
PubMed
12) 津島知靖・他:腎癌に対する化学療法・インターフェロン療法. 西日泌尿 47:362, 1985.
 
P.100 掲載の参考文献
1) Brice M II, Marshall V F, Green J L. and Whitmore W F Jr.:Simple total cystectomy for carcinoma of the urinary bladder. Cancer, 9:576-584, 1956.
 
2) Cordonnier J J.:Simple cystectomy in the management of bladder carcinoma. Arch. Surg. 108:190-191, 1974.
PubMed
3) Whitmore W F Jr, Batata M A, Ghoneim M A, Grabstald H. and Unal A.:Radical cystectomy with or without prior irradiation in the treatment of bladder cancer, J. Urol. 118:184-187, 1977.
 
4) 高安久雄, 小川秋実, 北川龍一, 柿沢至忠, 岸 洋一, 赤座英之, 石田仁男:膀胱腫瘍の治療成績. 日泌尿会誌 69:669-678, 1978.
 
5) 上門康成, 小川隆敏, 平野敦之,. 船岡信彦, 澤田佳久, 宮崎善久, 森 勝志, 戎野庄一, 新家俊明, 中村 順, 大川順正:膀胱癌症例おける膀胱全摘出術の治療成績. 日泌尿会誌 74:1509-1517, 1983.
 
6) Hohenfellner R. and Jacobi G H.:Radical cystectomy without preoperative radiotherapy for invasive bladder carcinoma-A justifed approach? In Progress and Controversies in Oncological Urology, p. 313-342, Alan R. Liss, Inc., New York, 1984.
 
7) Wajsman Z, Merrin C, Moore R. and Murphy G P.:Current results from treatment of bladder tumors with total cystectomy at Rosewell Park Memorial Institute. J. Urol. 113:806-810, 1975.
 
8) Pearse H D, Reed R R. and Hodges C V.:Radical cystectomy for bladder cancer. J. Urol. 119:216-218, 1978.
PubMed
9) Batata M A, Whitmore W F Jr, Chu F C H, Kim Y S, Hilaris B S. and Lee M Z.:Bladder cancer in men and women treated by radiation therapy and/or radical cystectomy. Urology, 18:15-20, 1981.
PubMed
10) Minervini R, Carlino F. and Fiorentini L.:Total cystectomy and ureterosigmoidostomy for carcinoma of the bladder. Eur. Urol. 9:80-83, 1983.
 
11) Whitmore W F Jr.:Management of invasive bladder neoplasms. Seminors in Urology, 1:34-41, 1983.
 
12) Lieskovsky G. and Skinner D G.:Role of lymphadenectomy in the treatment of bladder cancer. Urol. Clin. North. Amer. 11:709-716, 1984.
 
13) Whitmore W F Jr. and Marshall V F.:Radical total cystecomy for cancer of the bladder:209 consecutive cases five years later. J. Urol. 87:853-868, 1962.
 
14) Dretler S P, Ragsdale B D. and Leadbetter W F.:The value of pelvic lymphadenectomy in the surgical treatment of bladder cancer. J. Urol. 109:414-416, 1973.
PubMed
15) Laplante M. and Brice M II.:The upper limits of hopeful application of radical cystectomy for vesical carcinoma:Does nodal mtastasis always indicate incurability? J. Urol. 109:261-264, 1973.
 
16) Smith J A Jr. and Whitmore W F Jr.:Regional lymph node metastasis from bladder cancer, J. Urol. 126:591-593, 1981.
PubMed
17) Skinner D G.:Management of invasive bladder cancer. A meticulous pelvic node dissection can make a difference. J. Urol. 128:34-36, 1982.
PubMed
18) van der Werf-Messing B H P.:Carcinoma of the bladder T3 NX MO treated by preoperative irradiation followed by cystectomy. The report of the Rotterdam Radio-Therapy Institute. Cancer, 36:718-722, 1975.
 
19) Wallace D M. and Bloom H J G.:The management of deeply infiltrating (T3) bladder carinoma. Controlled trial of radical radiotherapy versus preoperative radiotherapy and radical cystectomy (first report). Brit. J. Urol. 48:587-594, 1976.
 
20) Miller L S.:Bladder cancer. Superiority of preoperative irradiation and cystectomy in clinical stage B2 and C. Cancer 39:973-980, 1977.
 
21) Skinner D G, Tift J P. and Kaufman J J.:High dose, short course preoperative radiation therapy and immediate single stage radical cystectomy with pelvic node dissection in the management of bladder cancer. J. Urol. 127:671-674, 1982.
PubMed
22) Yagoda A.:Chemotherapy for advanced urothelial cancer. Semimars in Urology, 1:60-74, 1983.
 
23) 新島端夫:膀胱腫瘍に関する実験的並びに臨床的研究. 日泌尿会誌 66:527-536, 1975.
 
24) 新島端夫, 小磯謙吉:膀胱腫瘍の治療, 癌と化学療法 5 499-508, 1978
Medical*Online
25) Denis L, Pavone-Macaluso M, DePouw M. and Members of the EORTC GU Group:Current status of bladder cancer protocols in the EORTC Genito-Urinary group. In Bladder Cancer, Part B:Radiation, Local and Systemic Chemotherapy, and New Treatment Modalities, pp. 429-439, Alan R. Liss Inc. New York, 1984.
 
26) Prout G R Jr. and Kopp J.:Resume of selected studies of the national bladder cancer collaborative group A and new protocols. In Bladder Cancer, Part B:Radiation, Local and Systemic Chemotherapy, and New Treatment Modalities, pp. 397-427, Alan R. Liss Inc. NewYork, 1984.
 
P.122 掲載の参考文献
1) Karnofsky DA:Clinical evaluation of anticancer drugs. Gann Monograph 2:223-234, 1966.
 
2) Kedia KR, Gibbons C and Persky L:The management of advanced bladder carcinoma. J Urol 125:655-658, 1981.
PubMed
3) Mulder JH, Foss SD, De Pauw§M and Van Oosterom AT:Cyclophosphamide, adriamycin and cisplatin combination chemotherapy in advanced bladder carcinoma, an EORTC phase II study. Eur J Cancer Clin Oncol 18:111-112, 1982.
 
4) Citrin DL, Hogan TF and Davis TE:A study of cyclophosphamide, adriamycin, cisplatinumand methotrexate in advanced transitional cell carcinoma of the urinary tract. Cancer 51:1-4, 1983.
PubMed
5) Kotake T, Usami M, Miki T, Kuroda M, Obata K, Osafune M, Fujioka H and Takasugi Y:Combination chemotherapy including adriamycin for advanced transitional cell carcinoma ofthe urinary tract. Cancer Chemother Pharmacol 11 Suppl:38-42, 1983.
 
6) Schwartz S, Yagoda A, Natale RB, Watson RC, Whitmore WF and Lesser M:Phase II trial of sequentially administered cisplatin, cyclophosphamide and doxorubicin for urothelial tract tumors. J Urol 130:681-684, 1983.
PubMed
7) Soloway MS, Einstein A, Corder MP, Bonney W, Prout GR Jr and Coombs J:A comparison of cisplatin and the combination of cisplatin and cyclophosphamide in advanced urothelial cancer. a National Bladder Cancer Collaborative Group Study, Cancer 52:767-772, 1983.
 
8) Gagliano R, Levin H, El-Bolkainy MN, Wilson HE, Stephens RL, Fletcher WS, Rivkin SE, O bryan RM, Coltman CA Jr, Saiki JH, Stuckey WJ, Balducci L, Bonnet JD and Dixon DO:Adriamycin versus adriamycin plus cis-diamminedichloroplatinum (DDP) in advanced transitional cell bladder carcinoma. A Southwest Oncology Group Study. Am J Clin Oncol 6:215-218, 1983.
 
9) 河合恒雄, 木原和徳, 鷲塚 誠, 小川一誠:膀胱癌. 現代の診療 26:98-103, 1984.
 
10) 藤岡秀樹, 多田安温, 中野悦次, 松田 稔, 長船匡男, 佐川史郎, 高羽 津, 園田孝夫:進行移行上皮癌に対する多剤併用化学療法-Cis-platinum, Cyclophosphamide, Adriamycin, 5-fluorouracil(CISCAF)の効果について-. 癌と化学療法 11:1612-1616, 1984.
Medical*Online
11) Sternberg CN, Yagoda A, Scher HI, Watson RC, Ahmed T, Weiselberg LR, Gellar N, Hollander PS, Herr HW, Sogani PC, Morse MJ and Whitmore WF:Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol 133:403-407, 1985.
 
12) Meyers FJ, Palmer JM, Freiha FS, Harker EG, Shortliffe LD, Hannigan J, McWhirter K and Torti FM:The fate of the bladder in patients with metastatic bladder cancer treated with cisplatin, methotrexate and vinblastine. A Northern California Oncology Group Study. J Urol 134:1118-1121, 1985.
 
13) Yagoda A:Chemotherapy of metastatic bladder cancer. Cancer 45:1879-1888, 1980.
 
14) Oliver RTD, Kwok HK, Highman WJ. and Waxman J:Methotrexate, cisplatin and carboplatin as single agents and in combination for metastatic bladder cancer. Brit J Urol 58:31-35, 1986.
 
15) Blumenreich MS, Yagoda A, Natale RB and Watson RC:Phase II trial of vinblastine sulfatefor metastatic urothelial tract tumors. Cancer 50:435-438, 1982.
PubMed
16) 太田和雄:抗癌剤の投与法 -理論とその臨床応用-, 持続投与. 癌と化学療法 12:798-805, 1985.
 
17) 佐竹一郎, 田利清信:進行前立腺癌に対するPeplomycinの持続皮下注入療法の検討. 泌尿紀要 31:875-883, 1985.
 
18) Lokich JJ:Phase I study of cis-diammine-dichloroplatinum (II) administered as a constant 5-day infusion. Cancer Treat Rep 64:905-908, 1980.
PubMed
P.130 掲載の参考文献
1) Whitmore, WF. Jr. Management of invasive bladder neoplasmas, Seminars in Urology, 1:34-41, 1983
 
2) 赤座英之, 小関清夫, 岸洋一, 梅田隆, 岩動孝一郎, 新島端夫, 浸潤性膀胱癌に対する集学的療法の成績. 日泌, 77:716-721, 1986
 
3) Herr, HW. Preoperative irradiation with and without chemotherapy as adjunct to radical cystectomy Urology, 25:127-134, 1985.
PubMed
P.141 掲載の参考文献
1) 岡島英五郎:膀胱腫瘍の診断・治療. 日本医事新報 No. 3031:8-13, 1982.
 
2) 小磯謙吉:膀胱癌, 進行癌における化学療法. 癌と化学療法 9:377-386, 1982.
Medical*Online
3) Whitmore W. F. Jr.:Management of invasive bladder neoplasms. Seminars in Urology 1:34-41, 1983.
PubMed
4) Yagoda A.:Chemotherapy for advanced urothelial cancer. Seminars in Urology 1:60-74, 1983.
 
5) Ito N, Hiasa Y, Tamai A et al.:Histogenesis of urinary bladder tumors induced by N-butyl-N-(4-hydroxybutyl) nitorosamine in rats. Gann 60:401-410, 1969.
 
6) 大園誠一郎, 夏目 修, 吉川元祥, 他:BBNによる膀胱腫瘍発育に対するCDDPを中心とした多剤併用投与の効果. 第23回日本癌治療学会総会抄録号, 448, 1985.
 
7) 長倉和彦, 木村 哲, 実川正道, 他:膀胱癌に対する超選択的動脈栓塞療法. 日泌尿会誌 72:141-150, 1981.
 
8) 藤岡秀樹, 多田安温. 中野悦次, 他:選択的膀胱動脈栓塞術を併用したTUSR-Btについて. 日泌尿会誌 75:424-430, 1984.
 
P.151 掲載の参考文献
1) Klopp, C. T., Alford, T. C., Bateman, J. and Berry, G. N.:Fractionated intra-arterial cancer chemotherapy with methyl bis amine hydrochloride;A preliminary report. Ann. Surg., 132:811-832, 1950.
PubMed
2) 白羽弥右衛門:抗癌剤の動脈内挿管投与. 癌の臨床, 2:534-543, 1956.
 
3) 高井修道, 小山達朗, 山下源太郎, 井川欣市:Nitramin及びChromomycin A(Toyomycin)の局所動脈内注射による膀胱腫瘍の治療. 日泌尿会誌, 51:1317-1323, 1960.
 
4) 長山忠雄:膀胱癌の治療法に関する研究 第1篇 膀胱癌に対する内腸骨動脈内持続注入についての基礎的研究. 日泌尿会誌, 61:271-283, 1970.
 
5) 三軒久義, 吉田利彦, 山田龍作, 山口真司:膀胱癌に対する新しい動注療法の試み. 医療, 37:1197-1200, 1983.
Medical*Online
P.162 掲載の参考文献
1) Yogota A.:Progress in Chemotherapy for Cancers of Urothelium. Urology 113 (supl. to April):118-123, 1983.
 
2) Wallace DM and Bloom HJG:The management of deeply infiltrating (T3) bladder carcinoma;controlled trial of radical radiotherapy versus preoperative radiotherapy and radical cystectomy. Brit. J Urol. 48:587-594, 1976.
 
3) Whitmore WF Jr. et al.:Radical cystectomy with or without prior irradiation in the treatment of bladder cancer. J Urol. 118-124, 1977.
 
4) Herr HW, et al.:Planned preoperative Cisplatin and radiation therapy for localy advanced bladder cancer. Cancer 52:2205-2208, 1983.
 
5) Raghavan D, et al.:Initial intravenous CIS-Platinum therapy:improved management for invasive high risk bladder caner. J Urol. 133:399-402, 1985.
 
6) 小磯謙吉:膀胱癌:進行癌における化学療法. 癌と化学療法 9:377-386, 1982.
Medical*Online
7) Ogata J. et al.:Treatment of carcinoma of the bladder by infusion of the anticancer agents (mitomycin-C) via the internal ilica artery. J Urol. 110:667-670, 1973.
 
8) 上門康成, 他:進行膀胱癌の化学療法-特に深部浸潤癌に対する根治的膀胱全摘除術にともなう補助化学療法を中心として. 泌尿紀要. 31:1365-1370, 1985. Adjuvant chemotherapy.
 
9) Hill DE. et al.:Radical cystectomy and adjuvant chemotherapy. Urology 15:151-154, 1985.
PubMed
10) Kotake T. et al.:Combination chemotherapy including Adriamycin for advanced transitional cell carcinoma of the urinary tract. Cancer chemother Pharmacol (suppl):S38-S42, 1983.
 
11) Sternberg CN, et al.:Preliminary result of M-VAC (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) for trnasional cell carcinoma of the urotherium. J. Urol. 13:403-407, 1985.
 
12) Ahmed T. et al.:Vinblastine and Methotrexate for advanced bladder cancer. J. Urol. 133:602-604, 1985.
PubMed
13) Soloway MS. et al.:Cis-diamminedichloroplatinum (II) in locally advanced and metastatic urotherial cancer. Cancer 47:476-480, 1981.
 
14) Logothetis CJ. et al.:Cyclophosphamide, Doxorubicine and Cisplatin chemotherapy for patients with locally advanced urotherial tumors with or without nodal metastasis. J Urol. 134:460-464, 1985.
PubMed
P.206 掲載の参考文献
1) 武田克治:前立腺癌におけるandrogen依存性のbiochemical indicatorとしての前立腺組織内androgen濃度に関する研究. 日泌尿会誌 76:1125-1137, 1985.
 
2) 吉本 純, 那須保友, 赤木隆文, 小浜常昭, 津島知靖, 尾崎雄治郎, 松村陽右, 大森弘之:進行Stage D前立腺癌に対するVincristine, Ifosfamide, Peplomycin併用療法. 日泌尿会誌 76:1-9, 1985
 
3) Logothetis C J, Samuels M L, von Eshenbach A C, Trinade A, Ogden S, Grant C. and Johnson DE.:Doxorubicin, mitomycin C and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer. J. Clin. Oncol. 1:368, 1983.
 
4) Yoshimoto J, Ochi J, Tanahashi T, Matsumura Y. and Ohmori H.:Alternating Combination Chemotherapy (VIP-DMF) for advanced prostatic cancer. J. Jpn. Soc. Cancer Ther. 21:482, 1986.
 
P.214 掲載の参考文献
1) Scott W W, Gibbons R P, Johnson D E, et al:The continued evaluation of the effects of chemotherapy in patients with advanced carcinoma of the prostate. J. Urol. 116 :211-213, 1976,
PubMed
2) Loening S A, Scott W W, Dekernion J, et al:A comparison of hydroxyurea, methyl-chloroethyl-cyclohexy-nitrosourea and cyclophsphamide in patients with advanced carcinoma of the prostate. J, Urol. 125 :812-816, 1981.
 
P.226 掲載の参考文献
1) 高安久雄, 志田圭三, 百瀬俊郎, 他:Estracytの前立腺癌に対する治療効果に関する臨床的検討. 西日泌尿 44:889-899, 1982.
 
2) 藤井昭男, 荒川創一, 濱見学, 他:Stage D前立腺癌に対するEndoxan (EDX)大量間歇療法, 日泌尿会誌 73:45-46, 1982.
 
3) 吉本純, 那須保友, 赤木隆文, 他:進行Stage D前立腺癌に対するVincristine, Ifosphamide, Peplomycin併用療法. 日泌尿会誌 76:1-9, 1985.
 
4) 宮川美栄子, 岡田謙一郎, 山内民男, 他:抗男性ホルモン療法に再燃した前立腺癌進行例に対する多剤併用療法の経験. 泌尿紀要 27:1297-1301, 1981.
 
5) Murphy, G. P. and Slack, N. H.:The questionable use of hormon therapy in advanced carcinoma of the prostate. Urologic Clinics of North America 7:631-638, 1980.
PubMed
6) Konyves, I., Muntzing, J. and Rozencweig, M.:Chemotherapy principles in the treatment of prostatic cancer. The prostate 5:55-62, 1984.
PubMed
7) Torti, F. M. and Lum, B. L:Chemotherapy in prostate cancer. pp. 125-161 in Genitourinary cancer Edited by Garnick, M. B. Churchill Livingstone, New York. 1985.
 
8) 斎藤 泰:再燃前立腺癌の治療. 臨泌 38:841-851, 1984.
 
9) 三馬省二, 吉川元祥, 二見孝, 他:cis-Diamminedichloroplatinum (II) 投与時の消化器症状に対するsteroidの効果. 癌と化学療法 12:561-565, 1985.
Medical*Online
10) Merrin C. E:Treatment of previously untreated (by hormonal manipulaion) stage D adenocarcinoma of the prostate with combined orchiectomy, estrogen, and cis-diamminedich-loroplatinum. Urology 15:123-126, 1980.
 
11) Yagoda, A., Watson R. C., Natale R. B., et. al.:A critical analysis of response criteria in patients with prostatic cancer treated with cis-diamminedichloride platinum II. Cancer 44:1553-1562, 1979.
 
12) 平尾佳彦, 平松侃, 貴宝院邦彦, 他:尿路性器進行癌に対するcis-diamminedichloroplatinum (II)(CDDP)の治療成績. 泌尿紀要 28 (Suppl. ):67-83, 1982.
 
P.234 掲載の参考文献
1) Schroder FH.:Experimental models in the study of prostatic cancer. In Prostate Cancer (G. H. Jacobi and R. Hohenfellner eds), pp 343-356, Williams & Willkins, Baltimore, 1982.
 
2) 岡田謙一郎, 橋村孝幸, 大石賢二:前立腺および前立腺由来細胞の培養, 実験医学のための動物培養細胞利用集成(遠藤浩良監修) pp287-293, R&Dプランニング, 東京, 1985.
 
3) Horoszewicz JS, Leong SS, Kawinski E, Karr JR, Rosenthal H, Chu TM, Mirand EA. and Murphy GP.:LNCap model of human prostatic carcinoma. Cancer Res. 43:1809-1818, 1983.
 
4) Shimozato Y, Kameya T, Nagai K, Hirohashi S, Koide T, Hayashi H. and Nomura T.:Transplantation of human tumors in nude mice. J. Natl. Cancer Inst. 56:1251-1260, 1976.
 
5) Hoehn W, Schroder FH. Riemann AC, Joebsis AC. and Hermanek P.:Some characteristics of a serially transplantable line in nude mice (PC-82) . Prostate 1:95-104, 1980.
 
6) Ito YZ. and Nakazato Y.:A new serially transplantable human prostatic cancer (HONDA) in nude mice. J. Urol. 132:384-387, 1984.
PubMed
7) Hoehn W, Wagner M, Riemann JF, Hermanek P, Williams E, Walther R. and Schrueffer R.:Prostatic adenocarcinoma PC EW, a new human tumor line transplantable in nude mice. Prostate, 5:445-452, 1984.
PubMed
8) Sarosdy MF, Lamm DM. Radwin HM. and von Hoff DD.:Clonogenic assay and in vitro chemosensitivity testing of human urologic malignancies. Cancer, 50:1332-1338, 1982.
 
9) Okada K, Yamauchi T. Oishi K. and Yoshida O.:Evaluation of chemotherapy of prostatic cancer in nude mice. Prostate suppl. 1:85-93, 1981.
PubMed
10) 岡田謙一郎, 吉田 修:ヌードマウスを用いた非ホルモン性抗癌剤による前立腺癌化学療法に関する研究. 泌尿紀要 25:993-1007, 1979.
 
P.237 掲載の参考文献
1) 内藤克輔, 久住治男, 三崎俊光, 島田宏一郎, 宮崎公臣, 小坂哲志, 宮城徹三郎:前立腺癌に対するUFTのphase II study. 癌と化学療法 12:1440-1444, 1985.
Medical*Online
2) Schmidt JD, Scott WW, Gibbons R, et al:Chemotherapy programs of the Natinal Prostatic Cancer Project (NPCD) . Cancer, 45:1937-1946, 1980.
 
P.256 掲載の参考文献
1) 吉田 修:1970年代の日本人睾丸(精巣)腫瘍の臨床統計. 泌尿紀要 31:337-354, 1985.
 
2) 吉田 修:睾丸胚細胞性腫瘍の治療. 胚細胞性腫瘍の基礎と臨床. (末桝恵一, 下里幸雄監修) pp. 133-147. 協和企画通信, 1986.
 
3) 吉田 修, 山内民男, 飛田収一:睾丸腫瘍の治療における問題点. 癌の臨床 31:1046-1050, 1985.
 
4) Pottern L M and Goedert J J:Epidemiology of testicular cancer in Principles and Management of Testicular Cancer (Javadpour Ed. ) . pp. 108-132, Thieme Inc., New York, 1986.
 
5) Farrer J H and Rajfer J:Cryptorchi dism and Testicular Cancer in Principles and Management of Testicular Cancer (Javadpour Ed. ) . pp. 133-154, Thieme Inc., New York, 1986.
 
6) 桐山啻夫, 吉田 修:わが国における睾丸悪性新生物による死亡の動向. 泌尿紀要 28:1337-1344, 1982.
 
7) 日本泌尿器科学会・日本病理学会編:睾丸腫瘍取扱い規約. 金原出版, 1984.
 
8) 岡田謙一郎, 吉田 修:尿路性器悪性腫瘍のヌードマウス異種移植組織の研究-移植成績と移植組織の検討-. 泌尿紀要 30:1749-1767, 1984.
 
9) Carter S K and Wasserman T H:The Chemotherapy of urologic cancer. Cancer 36:729-747, 1975.
PubMed
10) 吉田 修:睾丸腫瘍の診断と治療における最近の動向. 現代外科学大系, 1978-E, pp. 175-192, 1978.
 
11) Javadpour N and Young J D:Management of stage 2 nonseminomatous testicular cancer in Principles and Management of Testicula Cancer (Javadpour Ed. ) . pp. 243-249, Thieme Inc., New York, 1986.
 
12) Williams S D, Einhorn L H:Etoposide salvage therapy for refractory germ cell tumors:an update. Cancer Treat. suppl. A:67-71, 1982.
 
13) Hendry W S, Stedronska J, Jonas C R, Blackmore C A, Barrett A and Peckham M J:Semen analysis in testicular cancer and Hodgkin:s disease:Pre-and post-treatment findings and implications for cryopreservation. Brit. J. Urol. 55:769-773, 1983.
 
14) Glode L M, Robinson J and Gould S F:Protection from cyclophosphamideinduced testicular damage with an analogue of godotropin-releasing hormone. Lancet I:1132-1134, 1981.
PubMed
P.266 掲載の参考文献
1) Li M C, Whitomre W F, Jr., Golbey R. and Grabstald H.:Effects of combined drug therapy on metastatic cancer of the testis. J. Amer. Med. Asso. 174:1291-1299, 1960.
 
2) Samuels M L, Johnson D E. and Holoye P Y.:Continuous intravenous bleomycin (NSC-125066) therapy with vinblastine (NSC-49842) in stage III testicular neoplasia. Cancer Chemother. Rep. 59:563-570, 1975.
PubMed
3) Wittes R E, Yagoda A, Silvay O, Magill G B, Whitmore W, Krakoff I H. and Golbey R B.:Chemotherapy of germ cell tumors of the testis. 1. Induction of remissions with vinblastine, actiomycin D, and bleomycin. Cancer, 37:637-645, 1976.
 
4) Einhorn L H. and Donohue J.:Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann. Inter Med. 87:293-298, 1977.
 
5) Vugrin D, Herr H W, Whitmore W F, Jr., Sogani P C. and Golbey R B.:VAB-6 combination chemotherapy in disseminated cancer of the testis. Ann. Inter. Med. 95:59-61, 1981.
 
P.274 掲載の参考文献
1) Vugrin D, Herr H W, Whitmore W F jr, Sogani P C. and Golbey R B.:VAB6 Combination Chemotherapy in Disseminated Cancer of the Testis. Ann. Inter. Med. 95:59-61, 1981.
 
2) Vugrin D, Whitmore W F jr. and Gobley R B.:VAB-6 Combination Chemotherapy without Maintenance in Treatment of Disseminated Cancer of the Testis. Cancer 51:211-215, 1983.
 
3) 日本泌尿器科学会, 日本病理学会編:睾丸腫瘍取扱い規約. 金原出版, 東京 1984.
 
4) Williams SD, Einhorn LH, Greco FA, Oldham R. and Fletcher F:VP-16-213 Salvage Therapy for Germinal Neoplasms. Cancer 46:2154-2158, 1980.
 
5) Ozols RF, Deisseroth A B, Javadpour N, Barlock A, Messerschmit G L. and Youg RC.:Treatment of Poor Prognosis Non-seminomatous Testicular Cancer with a "High-Dose" Platinum Combination Chemotherapy Regimen. Cancer 51:1803-1807, 1983.
 
6) Lange P H, Vogelzang N J, Goldman A, Kennedy B J. amd Fraley E E.:Marker Half-life Analysis as a Prognostic Tool in Testicular Cancer. J. Urol. 128:708-711, 1982.
 
7) Sidi AA, Chiou R. and Lange P H.:Recent Reflections on Tumor Markers. World J. Urol. 2:18-25, 1984.
 
8) Einhorn L H. and Williams S D.:Chemotherapy of Disseminated Testicular Cancer:A Random Prospective Study. Cancer 46:1339-1344, 1980.
PubMed
9) 飛田収一, 川喜田睦司, 大石賢二, 岡田裕作, 竹内秀雄, 岡田謙一郎, 吉田 修:睾丸腫瘍の化学療法時におけるα-Fetoprotein(AFP)の偽陽性について. 泌尿紀要投稿中.
 
10) Bosl G J, Geller N, Cirrincione C, Hajdu S I, Whitmore W jr, Nisselbaum J, Vugrin D. and Golbey R B.:Interrelationships of Histopathology and other Clinical Varibles in Patients with Germ Cell Tumors of the Testis. Cancer 51:2121-2125, 1983.
 
11) Skinner D G.:Advanced Metastatic Testicular Cancer: the Need for Reporting Results According to Initial Extent of Disease. J. Urol. 128:312-314, 1982.
 
12) Vugrin D, Whitmore W F jr, Bains M. and Golbey R B.:Role of Chemotherapy and Surgery in the Treatment of Thoratic Metastases from Nonseminomatous Germ Cell Testis Tumor. Cancer 50:1057-1060, 1982.
 
13) Vugrin D. and Whitmore W F jr.:The Role of Chemotherapy and Surgery in the Treatment of Retroperitoneal Metastases in Advanced Nonseminomatous Testis Cancer. Cancer 55:1874-1878, 1985.
PubMed
14) Donohue J P, Einhorn L H. and Williams S D.:Cytoreductive Surgery for Metastatic Testis Cancer:Considerations of Timing and Extent. J. Urol. 123:876-880, 1980.
PubMed
15) Javadpour N, Ozols R F, Anderson T, Barlock A B, Wesley R. and Young R C.:ARandomized Trial of Cytoreductive Surgery Followed by Chemotherapy versus Chemotherapy Alone in Bulky Stage III Testicular Cancer with Poor Prognostic Features. Cancer 50:2004:2010, 1982.
 
P.305 掲載の参考文献
1) Rosenberg B. and Van Camp L.:The successfull regression of large solid sarcoma 180 tumors by platinum compounds. Cancer Res. 30:1799-1802, 1970.
 
2) Merrin C E.:Treatment of genitourinary tumors with cis-dichlorodiammineplatinum (II):Experience in 250 patients. Cancer Treat. Rep. 63:1579-1584, 1979.
PubMed
3) Prestayko A W, Crooke S T. and Carter S K.:Cisplatin current status and new developments. Academic Press, Inc., New York, 1980.
 
4) 鈴木和雄, 田島 惇, 阿曽佳郎, 小野佳成, 大島伸一, 藤田民夫, 名出頼男, 有吉 寛, 福島雅典, 太田和雄:CDDP腎毒性に関する臨床的検討-年令別および尿路変更の有無による比較. 日癌治 20:752-757, 1985.
 
5) 広田 豊:化学療法剤による副作用-造血器障害-. 日本臨床 517 (秋季増刊号):1042-1055, 1984.
 
6) Ozols R F, Corden B J, Jacob J, Wesley M N, Ostchega Y. and Young R C.:High dose cisplatin in hypertonic saline. Ann. Intern. Med. 100:19-24, 1984.
 
7) Kunin C M, Chesney R W, Craig W A, England A C. and DeAngelis C.:Enzymuria as a marker of renal injury and disease:Studies of N-acety-β-glucosaminidase in the general population and in patients with renal disease. Pediatrics, 62:751-760, 1978.
 
8) Schentag J J, Sutfin T A, Plaut M E and Jusko W J.:Early detection of aminoglycoside nephrotoxicity with urinary beta-2-microglobulin. J. Med. 9:201-210, 1978.
PubMed
9) Espinel C H.:The FENa test use in the differential diagnosis of acute renal failure. J. A. M. A. 236:579-581, 1976.
PubMed
10) 鈴木和雄:薬剤腎毒性の予知に関する研究-特にCDDP腎毒性について-. 日泌尿会誌 76:1795-1806, 1985.
 

書評

最近チェックした商品履歴

Loading...